Odyssey Therapeutics Reports Increased Losses and No Collaboration Revenue in Latest 10-Q Filing

Odyssey Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded no collaboration revenue for the quarter, a decrease from $959,000 in the same period last year. For the six months ended June 30, 2026, collaboration revenue also fell to zero from $2.9 million in the prior year. The company’s operating expenses increased to $95.3 million for the first half of 2026, compared to $84.0 million for the same period in 2025, primarily driven by higher research and development costs and changes in the fair value of contingent consideration.

The net loss for the second quarter of 2026 was $52.8 million, compared to a loss of $41.2 million in the same quarter of 2025. For the six-month period, the net loss was $91.1 million, up from $79.7 million in the previous year. The increase in losses was attributed to higher research and development expenses, which rose to $68.5 million for the first half of 2026, reflecting ongoing clinical trials and preclinical studies, particularly for its lead product candidates, OD-001 and OD-002.

Strategically, Odyssey Therapeutics completed its initial public offering (IPO) in May 2026, raising approximately $254.9 million in net proceeds. This capital infusion has bolstered the company’s cash position, with cash, cash equivalents, and marketable securities totaling $433.1 million as of June 30, 2026. The company anticipates that these funds will be sufficient to support its operations into the second half of 2028. The IPO also led to a significant increase in the number of common shares outstanding, with 47.9 million shares issued as of the end of the reporting period.

Operationally, Odyssey Therapeutics is focused on advancing its clinical programs, particularly OD-001, which is in a Phase 2a trial for ulcerative colitis, and OD-002, which is in IND-enabling studies. The company has also expanded its research capabilities and is actively pursuing additional collaborations to enhance its product pipeline. As of June 30, 2026, the company had a total employee headcount of 150, reflecting its growth and investment in talent to support its research and development efforts.

Looking ahead, Odyssey Therapeutics expects to continue incurring substantial losses as it progresses its product candidates through clinical trials and seeks regulatory approvals. The company acknowledges the inherent risks in drug development and the need for additional capital to sustain its operations and research initiatives. The management remains optimistic about the potential of its product candidates and the overall market opportunity in the autoimmune and inflammatory disease sectors.